Treatments and outcome for patients with PD
| Case no. . | Treatment . | Response . | Later CLL PD (treatment) . | Status . | PPS (mo) . |
|---|---|---|---|---|---|
| RT–DLBCL | |||||
| 1 | R-CHOP | PD | — | Dead | 2.3 |
| 2 | No treatment | — | — | Dead | 0.9 |
| 3 | Vin/Gem | PR | — | Alive | 32.3 |
| 4 | R-CHOP | SD | — | Dead | 24.6 |
| 5 | HyperCVAD | PD | — | Dead | 14.9 |
| 6 | R-CHOP | PD | — | Dead | 5.6 |
| 7 | OFAR | PD | — | Dead | 10.9 |
| 8 | CHOP + AlloSCT | PR | — | Dead | 13 |
| 9 | R-ICE + AuSCT | CR | + (Novel BTKI on trial) | Alive | 36.9 |
| 10 | R-ICE + AuSCT | CR | + (Ibr) | Alive | 45.0 |
| 11 | XRT + R-MVP | PR | + (Ibr) | Alive | 40.5 |
| 12 | R-CHOP | SD | — | Dead | 9.3 |
| 13 | R-CHOP | Death | — | Dead | 1 |
| 14 | R-ICE | SD | — | Dead | 10.7 |
| RT-HL | |||||
| 15 | ABVD | CR | — | Alive | 29.3 |
| 16 | R-CHOP + AlloSCT | CR | — | Alive | 49.9 |
| 17 | CHEP + XRT | CR | + (Ibr) | Alive | 30.2 |
| CLL progression | |||||
| 1 | No treatment | — | — | Dead | <1.0 |
| 2 | Ibr | SD | + | Dead | 11.4 |
| 3 | Ibr | PR | — | Alive | 6.2 |
| 4 | FCR | Unk | — | Dead | 5.6 |
| 5 | Ibr | PR | — | Dead (toxicity) | 8.6 |
| 6 | Ibr | PR | — | Alive | 15.7 |
| 7 | Ibr | PR | — | Alive | 13.2 |
| 8 | Ibr | PR | — | Dead (toxicity) | 8.3 |
| Case no. . | Treatment . | Response . | Later CLL PD (treatment) . | Status . | PPS (mo) . |
|---|---|---|---|---|---|
| RT–DLBCL | |||||
| 1 | R-CHOP | PD | — | Dead | 2.3 |
| 2 | No treatment | — | — | Dead | 0.9 |
| 3 | Vin/Gem | PR | — | Alive | 32.3 |
| 4 | R-CHOP | SD | — | Dead | 24.6 |
| 5 | HyperCVAD | PD | — | Dead | 14.9 |
| 6 | R-CHOP | PD | — | Dead | 5.6 |
| 7 | OFAR | PD | — | Dead | 10.9 |
| 8 | CHOP + AlloSCT | PR | — | Dead | 13 |
| 9 | R-ICE + AuSCT | CR | + (Novel BTKI on trial) | Alive | 36.9 |
| 10 | R-ICE + AuSCT | CR | + (Ibr) | Alive | 45.0 |
| 11 | XRT + R-MVP | PR | + (Ibr) | Alive | 40.5 |
| 12 | R-CHOP | SD | — | Dead | 9.3 |
| 13 | R-CHOP | Death | — | Dead | 1 |
| 14 | R-ICE | SD | — | Dead | 10.7 |
| RT-HL | |||||
| 15 | ABVD | CR | — | Alive | 29.3 |
| 16 | R-CHOP + AlloSCT | CR | — | Alive | 49.9 |
| 17 | CHEP + XRT | CR | + (Ibr) | Alive | 30.2 |
| CLL progression | |||||
| 1 | No treatment | — | — | Dead | <1.0 |
| 2 | Ibr | SD | + | Dead | 11.4 |
| 3 | Ibr | PR | — | Alive | 6.2 |
| 4 | FCR | Unk | — | Dead | 5.6 |
| 5 | Ibr | PR | — | Dead (toxicity) | 8.6 |
| 6 | Ibr | PR | — | Alive | 15.7 |
| 7 | Ibr | PR | — | Alive | 13.2 |
| 8 | Ibr | PR | — | Dead (toxicity) | 8.3 |
ABVD, doxorubicin, bleomycin, vinblastine, dacarbazine; AlloSCT, allogeneic stem cell transplant; AuSCT, autologous stem cell transplant; BGB, BGB-3111, an experimental BTK inhibitor, as part of a phase 1 clinical trial (NCT02343120); CHEP, cyclophosphamide, doxorubicin, epirubicin, prednisolone; Gem, gemcitabine; Ibr, ibrutinib; OFAR, oxaliplatin, fludarabine, cytarabine, and rituximab; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone; R-ICE, rituximab, ifosfamide, carboplatin, etoposide; R-MVP, rituximab, mitoxantrone, vincristine, prednisolone; Unk, unknown; Vin, vinorelbine; XRT, involved-field radiation therapy.